FORT COLLINS, Colo. & ATLANTA--(BUSINESS WIRE)--Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company’s experimental chikungunya virus (CHIKV) vaccine. Data presented here demonstrate that the vaccine is safe and generates protective immune responses after a single dose in several validated animal models of CHIKV infection. The meeting is being held from November 3-7, 2010 in the Marriott Atlanta Marquis Hotel in Atlanta, Georgia.
